COMPASS PathwaysCMPS
Recorded

COMPASS Pathways 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration29 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisManaging Director and Head of Therapeutics Research

Great. Thanks very much. Super happy to be moderating this chat with the COMPASS Pathways team. With me is Steve Levine, Chief Patient Officer, and Lori Englebert, Chief Commercial Officer. COMPASS just got the NDA submission in, so congratulations on that. Happy to kick it over to whoever wants to start, but I think the most interesting conversation here really just sort of centers around what you're doing right now with launch prep and stuff like that. So, feel free to take it away.

Steve LevineChief Patient Officer

You want to start? Yeah, I'll start and, of course, make the obligatory statement that we may make forward-looking statements, so please refer to the investor page of our website.

Paul MatteisManaging Director and Head of Therapeutics Research

Can I just, since we know each other so well. I saw a really funny thing online today that said, "Biotech companies lead off by saying, 'We're making forward-looking statements,' and AI companies lead off by saying, 'We are curing cancer, all cancer in the next 10 years.'" I was like, "That is awesome.

Steve LevineChief Patient Officer

Nonetheless- Do you want us to jump in?

Steve LevineChief Patient Officer

This is for SEC filing.

Paul MatteisManaging Director and Head of Therapeutics Research

Sure, that's fine. But anyways, it just reminded me of it.

Steve LevineChief Patient Officer

We're going to cure cancer.

Lori EnglebertChief Commercial Officer

We're lawyered up much more than the AI companies are, right?

Paul MatteisManaging Director and Head of Therapeutics Research

Yeah. Apparently, yeah. That's all.

Paul MatteisManaging Director and Head of Therapeutics Research

With that, go ahead. Yeah.

Steve LevineChief Patient Officer

First, for those that aren't familiar with COMPASS Pathways, we are a biotechnology company that has been developing a synthetic proprietary formulation of psilocybin that we call COMP360. Earlier this week, we announced that we have completed the submission of our NDA, which we had already been submitting on a rolling basis and has been reviewed on a rolling basis, for our lead indication in treatment-resistant depression. This represents two large phase III studies and supported by a large phase II, in which we have demonstrated a generally safe and well-tolerated profile with a very highly differentiated set of efficacy outcomes with very rapid onset of effect, detected as of the first measured time point, 24 hours after the first administration.

Steve LevineChief Patient Officer

And with data now out to up to 52 weeks, demonstrating that with just up to a few administrations in a year, there may be durable efficacy with a frequency of treatment that we've never seen before. We are very excited for the ongoing review of this application under our national priority review voucher. This potentially is a contracted review period, and with that, we've been very busy preparing for commercialization, which I will hand over to Lori.

Lori EnglebertChief Commercial Officer

Yeah, you want me to just keep rolling?

Lori EnglebertChief Commercial Officer

Please. Before we keep going, I just want to say, if Steve and I act like we share a brain, we do.

Lori EnglebertChief Commercial Officer

Because we do. He is a real psychiatrist.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day